The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

A study conducted on over 77,000 individuals found that alcohol consumption increased the risk of dry eye in women.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and ...

Enhanced monofocal IOLs provide a slight depth-of-focus boost without compromising contrast, making them a versatile choice ...

Himani Goyal, MD, assesses the benefits of proactive glaucoma management through interventional procedures beyond traditional treatments, focusing on treatment customization based on factors such as ...

Eyebright Medical's Loong Crystal PR IOL received Class III certification from China's NMPA, indicating high regulatory ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.